

Supports Neurological Development Via Methylation Cycle & The Collateral Pathways

Key Features:

- With key cofactors of multiple metabolic pathways implicated in the clinical presentations of ASD & ADHD.
- Supports the collateral metabolic pathways of the methylation cycle and reduce the symptoms of metabolic overload from methylation enhancement.
- The inclusion of *S. boulardii* helps to support the gut flora in cases of opportunistic bacteria overgrowth, particularly *Clostridium spp.* and *Candida albicans*.

Indication:

Support the neurological development of patients with attention deficit hyperactivity disorder (ADHD), autism spectrum disorders (ASD), and other neurological disorders.

Description:

Modism is a comprehensive formula designed to support multiple biochemical pathways of neurotransmitters and metabolic intermediates, enhance antioxidant capacity and help restore healthy microbiota; all of which have been implicated in the clinical presentations of autism spectrum disorders (ASD) and ADHD.

1) Methylation Pathway (MTHFR)

Methylation is one of the most important biochemical reactions in the human body. It is involved in DNA turnover, neurotransmitter synthesis and reduction, detoxification, and tissue regeneration. Therefore, dysfunction in methylation can result in a collection of symptoms or conditions, such as mental/ mood disorders, neurological disorders, cardiovascular disease, and cancers.

MTHFR polymorphisms (A1298C or/and C677T) are one of the most common causes of insufficient methylation. Conditions involving MTHFR dysfunction may include cardiovascular diseases, ASD, ADHD, cancers (eg. breast, prostate, colon, and brain), anxiety, depression, and schizophrenia. Both C677T and A1298C, in particular, have been shown closely associated with ASD¹ and ADHD⁹.

Active 5-MTHF with other methyl-donors (ie. methyl-cobalamin, betaine) can be used to feed into and drive the methylation cycle.

However, when we enhance solely the methylation cycle, all of the collateral pathways [Figure 1] will be upregulated and require more supplementation of cofactors. Failure to address the whole picture can overload the collateral pathways and worsen the symptoms. With already compromised metabolism of several neurotransmitters, unsupported collateral pathways may further amplify the symptoms of ASD and ADHD.

Serving Size: 1 scoop (4.2 g)

42 servings per container

Ingredients (per scoop):

Vitamin B1 (from thiamine HCl).....	10 mg
Vitamin B2 (from riboflavin-5'-phosphate).....	10 mg
Vitamin B3 (Niacinamide).....	25 mg
Vitamin B6 (from calcium pyridoxal-5'-phosphate).....	25 mg
5-MTHF (from calcium 5-methylfolate).....	250 mcg
Vitamin B12 (methylcobalamin).....	250 mcg
Vitamin D3 (cholecalciferol) (12.5 mcg).....	500 IU
Magnesium (from magnesium citrate).....	125 mg
Molybdenum (from molybdenum glycinate).....	200 mcg
Copper (from copper bisglycinate).....	200 mcg
Zinc (from zinc gluconate).....	6 mg
Taurine.....	200 mg
Betaine Anhydrous.....	400 mg
<i>Saccharomyces boulardii</i>	5 billion cfu

Other Ingredients: Silicon dioxide, erythritol, citric acid, stevia, natural passion fruit flavor

Suggested Use: Take 1 scoop, 1-2 times daily, away from other medications, or as directed by your health care practitioner.

2) Catecholamine Metabolism (COMT, MAO)

Cofactors Required: B2, B6, Vit C, Mg

Catechol-O-Methyltransferase (COMT) and Monoamine Oxidase (MAO) work together to metabolize neurotransmitters such as histamine, dopamine, norepinephrine, and serotonin.

Enhanced methylation would increase activity of the biopterin cycle and consequently increase the output of catecholamines (ie. epinephrine and norepinephrine), and, without nutrient support in COMT and MAO, could worsen anxiety, agitation, and aggression in ASD & ADHD patients.


3) Histamine Reduction (HNMT, DAO, MAO)

Cofactors Required: B1, B6, Cu, Mg, Vitamin C

Histamine plays 3 major roles in the body: immune response (via IgE antibodies), neurotransmitter (increase wakefulness), and promoting stomach acid secretion. It is metabolized by 3 major enzymatic pathways:

- histamine-N-methyltransferase (HNMT)** – responsible for histamine metabolism in the central nervous system (CNS); requires SAMe.
- diamine oxidase (DAO)** – requires Vitamin B6 and Copper; works outside the CNS.
- monoamine oxidase (MAO)** – requires vitamin B6, magnesium, and vitamin C; works inside the CNS.

Histaminergic system is implicated in many neurological disorders including Tourette syndrome and






Figure 1. Methylation cycle and its collateral pathways.

ASD. Therefore, it is important to supply cofactors for all 3 histamine reduction pathways, especially when the methylation cycle is enhanced.

4) Sulfite Metabolism via Sulfite Oxidase (SUOX)

Cofactor Required: Mo

Enhanced methylation can increase homocysteine production. Homocysteine is either metabolized into cysteine to make glutathione and taurine (involving Mg, B3, B6) or **converted into “sulfite”, the toxic form of sulfur**. Sulfite requires **molybdenum (Mo) as a cofactor in SUOX** to be converted into sulfate – the beneficial form of sulfur.

Patients with unsupported sulfite metabolism may experience symptoms of sulfite sensitivities, such as asthma attack, allergic rhinitis, hives and swollen eyes, and anaphylaxis (rarely).

5) Dysbiosis & Autism Spectrum Disorders (ASD)

A growing body of studies has demonstrated a positive correlation between gut dysbiosis, particularly Clostridium and Candida overgrowth^{2,3}, and ASD. The proposed mechanism is Clostridia's continuous secretions of neurotoxins into the system damaging the neurons and halting normal development.⁶ There is also evidence showing the Clostridium overgrowth as the result of environmental glyphosate toxicity, as well as long-term antibiotic use, in autistic toddlers.

Saccharomyces boulardii - a yeast probiotic - is clinically used in treating antibiotic-associated diarrhea caused by Clostridium overgrowth, as well as restoring the gut microbiota from chronic dysbiosis.⁸ It is able to neutralize multiple toxins produced by *Clostridium difficile* and *Candida albicans*, as well as inhibit their growth,^{7,12} and hence, it may prove to be useful in improving the clinical outcomes of ASD.

For Education Purpose Only: The entire contents are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this presentation. All statements in this article have not been evaluated by the Food and Drug Administration and are not intended to be used to diagnose, treat, or prevent any diseases.

6) Anti-Oxidative Capacity & Mitochondrial Support

Cofactors Required: Cu, Mn, Zn, Vitamin B3, Taurine

Nitric oxide (NO) synthesis is upregulated via the **biopterin cycle** as the methylation cycle is enhanced. The superoxide radicals from NO synthesis then can increase the nutrient demand in SOD and GST pathways. Moreover, ASD patients have been found to have low levels of glutathione and SOD rendering them susceptible to inflammation and toxins.^{10,11}

Glutathione-S-Transferase (GST) is the enzyme that, with the help of niacinamide, catalyzes the reduction of oxidized glutathione (GS-SG ==> 2x GSH) – restoring glutathione to its active form.

Superoxide Dismutase (SOD) utilizes copper, zinc, or manganese as its cofactors depending on its types (ie. 1 to 3) and locations (ie. cytoplasm, mitochondria, and extracellular). It converts radicalized O₂ to the less active H₂O₂.

Taurine is a potent mitochondrial antioxidant. Mitochondrial dysfunction is commonly implicated in ASD and many other neurological conditions.

The rates of ADHD and ASD have been rising exponentially in the past decade. Both environment and the genetics seem to be at the center of the disease development. Therefore, it is important to address the multi-faceted mechanisms of the ASD and ADHD pathogenesis.

Reference:

- El-baz F, El-Aal MA, Kamal TM, Sadek AA, Othman AA. Study of the C677T and A1298C polymorphic genotypes of MTHFR gene in autism spectrum disorder. *Electron Physician*. 2017 Sep; 9(9): 5287-5293.
- Finegold et al. Gastrointestinal microflora studies in late-onset autism. *Clinical Infectious Diseases*. 2002; 35(1): S6-S16.
- Hughes HK, Ashwood P. Anti-Candida albicans IgG antibodies in children with autism spectrum disorders. *Front Psychiatry*. 2018 Nov; 9:627.
- Murakami S. Role of taurine in the pathogenesis of obesity. *Mol Nutr Food Res*. (2015); 59(7): 1353-63.
- Stout C, Charles A. Modulation of intercellular calcium signaling in astrocytes by extracellular calcium and magnesium. *Glia*. (2003); 43(3): 265-73.
- Argou-Cardozo I, Zeidan Chulia F. Clostridium bacteria and autism spectrum conditions: a systematic review and hypothetical contribution of environmental glyphosate levels. *Med Sci (Basel)*. 2018 Apr; 6(2).
- Castagliuolo I, Riegler MF, Valenck L, LaMont JT, Pothoulakis C. *Saccharomyces boulardii* Protease inhibits the effects of *Clostridium difficile* toxins A and B in human colonic mucosa. *Infection and Immunity*. Jan 1999; 60:302-307.
- Ehrhardt el al. *Saccharomyces boulardii* to prevent antibiotic-associated diarrhea: a randomized, double-masked, placebo-controlled trial. *Open Forum Infect Dis*. Jan 2016; 3(1): ofw011.
- Gokcen C, Kocak N, Pekgor A. MTHFR gene polymorphisms in children with attention deficit hyperactivity disorder. *Int J Med Sci*. 2011; 8(7):523-528.
- Wang L, Jia J, Zhang J, Li K. Serum levels of SOD and risk of ASD: a case-control study. *Int J Dev Neurosci*. 2016 Jun; 51:12-16.
- Kern JK, Geier DA, Adams JB, Garver CR, Audhya T, Geier MR. A clinical trial of glutathione supplementation in autism spectrum disorders. *Med Sci Monit*. 2011; 17(12): CR677-682.
- Murzyn A, Krasowska A, Stefanowicz P, Dziadkowiec D, Lukaszewicz M. Capric acid secreted by *S. boulardii* inhibits *C. albicans* filamentous growth, adhesion and biofilm formation. *PLoS One*. 2019 Aug; 5(8): e12050.